Richard Marsden says he will give a full update on the recent data from its Covid treatment trial when he presents to the American Thoracic Society (ATS).
Standard of care for Covid has changed from the phase 1 study in 2020 to now, with people getting out of hospital much more quickly, he explains.
In view of that, the focus now is to stop deterioration in certain patients, an area where the trial indicated Synairgen’s candidate can have a benefit.